Plakophilin-2 (pkp2) gene therapy using aav vector
AssigneeSpacecraft Seven, LLC
InventorsChristopher Dean HERZOG, Chester Bittencort SACRAMENTO, Raj PRABHAKAR, David RICKS
Life of this patent
Estimating the term…
Abstract
Provided herein is a gene therapy for PKP2 (Plakophilin-2), e.g. using an adeno-associated virus (AAV) vector. The promoter of the vector may be a MHCK7 promoter or a cardiac troponin T (HTNNT2) promoter. The capsid may be an AAV9 or AAVrh74 capsid or a functional variant thereof. Other promoters or capsids may be used. Further provided are methods of treatment, such as by intravenous, intracoronary, intracarotid or intracardiac administration of the rAAV vector, and other compositions and methods.
Claims14
1-91. (canceled)
A method of treating arrhythmogenic cardiomyopathy (ACM) in a subject having a mutation in a PKP2 gene, comprising:
- administering to the subject a recombinant adeno-associated virus (rAAV) vector comprising a vector genome,
- wherein the vector genome comprises an expression cassette and flanking AAV inverted terminal repeats (ITRs), the expression cassette comprising a polynucleotide which comprises:
- a polynucleotide sequence encoding a Plakophilin-2 (PKP2);
- a promoter sequence, wherein the promoter sequence is operatively linked to the polynucleotide sequence encoding the PKP2, and wherein the promoter sequence shares at least 98% polynucleotide sequence identity with SEQ ID NO:
- 31;
- and a poly A sequence;
- and
- wherein the rAAV vector is a recombinant AAV9 vector.
The method of claim 100, wherein the rAAV vector is administered by intravenous administration.
Dependencies are inferred from the claim text.